Clinical trials: Neoplasm Recurrence
Refractory, Multiple Myeloma
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to assess the safety/tolerability and determine the Japanese recommended dose (RD) of bortezomib administered as a once-daily intravenous bolus twice weekly for 2 consecutive weeks(Days 1, 4, 8, and…
- Conditions
- Refractory, Multiple Myeloma, Relapse
- Trial name
- NCT00752518
- Testing
- bortezomib
- Volunteers
- 35 people
- Sponsor
- Janssen Pharmaceutical K.K.
Esophageal Cancer
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or…
- Trial name
- NCT06769113
- Testing
- HLX43
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Henlius Biotech
Diffuse Large B-cell Lymphoma
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma…
- Trial name
- NCT05498220
- Testing
- Polatuzumab vedotin (PV), Rituximab, Hyaluronidase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of the study is to evaluate the comparability of efficacy, safety, and immunogenicity of RPH-002 and Erbitux® when administered in combination with docetaxel and cisplatin as first-line therapy in patients…
- Trial name
- NCT07435324
- Testing
- RPH-002, Erbitux®, Cisplatin
- Where
- 34 sites in Russia, Uzbekistan
- Volunteers
- 161 people
- Sponsor
- R-Pharm
Recurrent IDH1/2 Mutated Glioma
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation
Glioma are the most commun frequent brain tumour. Mutation of Isocitrate DeHydrogenase IDH1 or IDH2 genes affect 40% of gliomas, mostly grade II and III gliomas.
- Trial name
- AGIR (NCT03666559)
- Testing
- Azacitidine
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardio-cerebrovascular Disease
Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation
The aim of this study is to evaluate the efficacy of proton pump inhibitor (PPI), comparing to the mucosal defensive drug, in the prevention of the recurrence of gastric and/or duodenal ulcers during 12 weeks observation in…
- Trial name
- CARE (NCT01051388)
- Testing
- Low-dose PPI (Rabeprazole sodium), High-dose PPI (Rabeprazole sodium), Non-PPI (Gefarnate)
- Where
- Japan
- Volunteers
- 280 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
This phase I/II trial studies the side effects and best dose of sorafenib tosylate and bevacizumab and to see how well they work in treating patients with advanced kidney cancer.
- Conditions
- Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT00126503
- Testing
- Bevacizumab, Sorafenib Tosylate, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Portal Vein Thrombosis, Local Cause
Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause.
In case of acute portal vein thrombosis (PVT) prothrombotic factors are identified in about 60% of cases, while a local condition is present in 30% of cases.
- Trial name
- LOCAPORT (NCT05360641)
- Where
- France
- Volunteers
- 154 people
- Sponsor
- University Hospital, Caen
Esophageal Squamous Cell Carcinoma
Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)
This is a phase 2 trial investigating the effect and safety of afatinib in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.
- Trial name
- NCT03940976
- Testing
- Afatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Ovarian Carcinoma, Fallopian Tube Cancer
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
This is a phase-I clinical trial to determine the feasibility and safety of Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01312376
- Testing
- OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer, Neoplasms
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
IT141 is a novel nanoparticle formulation of SN-38, the active metabolite of irinotecan, and is intended to deliver more drug to the tumor with reduced toxicity on normal tissues.
- Conditions
- Cancer, Neoplasms, Tumors, Refractory Solid Tumors
- Trial name
- NCT03096340
- Testing
- IT-141
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Intezyne Technologies, Inc.
Prostate Cancer
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00471718
- Testing
- ABT-751
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer, Solid Tumor
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and…
- Conditions
- Cancer, Solid Tumor, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT05708924
- Testing
- FT538, Enoblituzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Low Grade Serous Carcinoma
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
This is a phase II, single arm, multi-centre study to assess the efficacy of pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal…
- Conditions
- Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- PERCEPTION (NCT04575961)
- Testing
- Pembrolizumab
- Where
- 2 sites in Germany
- Volunteers
- 33 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Lymphoma
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Interferon-alfa may interfere with the growth of cancer cells. Giving interferon-alfa following chemotherapy and peripheral stem cell transplantation may be an effective treatment for Hodgkin's disease or non-Hodgkin's…
- Trial name
- NCT00003924
- Testing
- recombinant interferon alfa
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 360 people
- Sponsor
- Lymphoma Study Association
Colorectal Cancer
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of colorectal cancer.
- Trial name
- NCT00030524
- Testing
- gefitinib
- Where
- 2 sites in United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Triple-Negative Breast Cancer (TNBC)
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
- Trial name
- NCT06732323
- Testing
- ESG401, Investigator's Choice Chemotherapy
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Small Cell Lung Cancer, Platinum-sensitive
A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
This study is being done to evaluate the good and bad effects of BIBF1120 in recurrent, platinum-sensitive small cell lung cancer patients and to see if BIBF1120 may or may not be more effective and better tolerated than standard…
- Trial name
- NCT02152059
- Testing
- BIBF1120
- Where
- Canada
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma, Glioma
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
This is a phase II study to determine the immunogenicity and efficacy of a vaccine composed of tumor associated long synthetic peptides mixed with Montanide ISA-51 VG administered with polyinosinic-polycytidylic acid …
- Trial name
- NCT02754362
- Testing
- Bevacizumab, Peptide Vaccine, Poly-ICLC as immune adjuvant
- Where
- United States
- Sponsor
- NYU Langone Health
Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
This is an open-label, multi-cohort, multi-center Phase Ib/II clinical study to evaluate the tolerance and efficacy of Mitoxantrone Hydrochloride liposome injection combined with cytarabine in patients with Acute Myeloid Leukemia…
- Trial name
- NCT05100303
- Testing
- Mitoxantrone Hydrochloride liposome injection, Cytarabine (LoDAC)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.